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Introduction {#sec006}
============

In-stent restenosis (ISR) is considered as the leading problem after percutaneous coronary intervention (PCI), especially in patients with type 2 diabetes mellitus (T2DM)\[[@pone.0155273.ref001],[@pone.0155273.ref002]\]. Thiazolidinediones (TZDs), agonists of the peroxisome proliferation-activated receptor-γ (PPAR-γ), usually used to improve insulin sensitivity and reduce blood glucose levels in diabetic patients, could also inhibit proliferation and migration of vascular smooth muscle cells (VSMCs) and ameliorate inflammation after vascular injury\[[@pone.0155273.ref003]--[@pone.0155273.ref005]\]. Among the three TZDs, pioglitazone may be the only one which shows beneficial effects on cardiovascular outcomes and appears to be promising in clinical application\[[@pone.0155273.ref006]--[@pone.0155273.ref008]\]. Previous meta-analysis has suggested that pioglitazone is effective in decreasing ISR and the need for revascularization after bare-metal stents (BMS) implantation in diabetic patients\[[@pone.0155273.ref009]\]. However, drug-eluting stents (DES) are more widely used in recent years. Diabetes mellitus was also regarded as one of the most powerful clinical predictors of ISR after DES implantation as same as in BMS era\[[@pone.0155273.ref010]--[@pone.0155273.ref012]\]. A hypothesized independent anti-restenotic effect of pioglitazone in patients with T2DM has not been clearly demonstrated\[[@pone.0155273.ref013]\]. Thus, we performed this meta-analysis to investigate the effect of pioglitazone on prevention of ISR in patients with T2DM after PCI, with update information both on BMS and DES implantation.

Methods {#sec007}
=======

This meta-analysis was conducted according to the PRISMA statement \[[@pone.0155273.ref014]\], and the PRISMA checklist is provided as [S1 Table](#pone.0155273.s001){ref-type="supplementary-material"}.

Search Strategy {#sec008}
---------------

We searched the databases including PubMed (<http://www.ncbi.nlm.nih.gov/pubmed>), EMBASE ([http://www.embase.com](http://www.embase.com/)), Cochrane Library ([www.cochranelibrary.com](http://www.cochranelibrary.com/)) and ISI Web of Science ([http://www.webofknowledge.com](http://www.webofknowledge.com/)) for all full-text published relevant studies compared the effect of pioglitazone with control group (placebo or no pioglitazone treatment) in T2DM patients after PCI through October 2015. Search terms included any possible combination of the keywords of ''restenosis", ''percutaneous coronary intervention or PCI", ''pioglitazone" and ''diabetes".

Study selection {#sec009}
---------------

Two independent reviewers (S.-J.Z. and L.C.) were involved in the search for potentially eligible studies and in the inclusion process. In case of disagreement, a decision was made under the supervision of the senior author (W.T.). Studies will be included if they met the following criteria: (1) RCT or high quality retrospective study, (2) pioglitazone was administered and compared with control group (placebo or no pioglitazone treatment) for patients who suffered from diabetes and performed PCI, and (3) the studies included at least one of the following interesting outcomes: ISR (defined as stenosis more than 50% at the site of stent), late loss (change in minimum lumen diameter at the stent site from baseline to follow-up), in-stent neointimal volume (neointimal volume/length of stent) measured by intravenous ultrasound (IVUS), target lesion revascularization (TLR) and major adverse cardiac events (MACE, including target vessel revascularization, acute myocardial infarction, cardiac death, etc.).

Data abstraction and quality assessment {#sec010}
---------------------------------------

For all included studies, we recorded the baseline information of the study, including the number of subjects, patients' characteristics, interventions in each group, methodology quality of the study, outcomes with ascertained method and length of follow-up. The data were extracted independently by two authors(S.-J.Z. and L.C.) using a pre-designed data extraction form. As before, disagreements will be resolved by discussion and referral to the senior author(W.T.) if necessary.

Statistical analysis {#sec011}
--------------------

The treatment effect for continuous outcomes are expressed as weighted mean difference (WMD) with 95% confidence intervals (CI) for all studies used the same scale\[[@pone.0155273.ref015]\]. For dichotomous data, the pooled risk ratios (RRs) would be used. Statistical heterogeneity across the studies was measured by I^2^ test, and a fixed-effects (FE) model (Mantel-Haenszel method) would be used if I^2^≤50%. In case of important heterogeneity (50%\<I^2^≤75%), further exploration was made if appropriate, including sensitivity analysis and subgroup analysis. If heterogeneity remained significant, a random-effects (RE) model would be used. If there was considerable heterogeneity (I^2^\>75%), the data would be regarded as unsuitable for pooling\[[@pone.0155273.ref015]\]. The publication bias was evaluated by using funnel plots with Begg's test\[[@pone.0155273.ref016]\]. A value of P\<0.05 indicated statistically significant. All analysis was completed in Stata v12.0 (Stata Corp, College Station, TX,USA) using the metan function.

Results {#sec012}
=======

Baseline characteristics of included studies {#sec013}
--------------------------------------------

Our search strategy resulted in the initial identification of 125 records. After duplicated removal, 91 studies were left, in which 81 records were further excluded as non-clinical studies, reviews, case reports or irrelevant studies after the title and abstract screening. As a result, a total of 10 studies were left for full-text screening to determine eligibility for analysis.

After full-text screening, 4 studies were removed due to either inappropriate set of experimental group, lack of interested outcome or other reasons\[[@pone.0155273.ref017]--[@pone.0155273.ref020]\]. Finally, 6 studies (5 RCTs and 1 retrospective study) involved a total of 503 cases, were selected for inclusion in the meta-analysis. A flow chart summarizes the selection process of the studies ([Fig 1](#pone.0155273.g001){ref-type="fig"}), and the detail information of the included studies is provided in [Table 1](#pone.0155273.t001){ref-type="table"}\[[@pone.0155273.ref021]--[@pone.0155273.ref026]\].

![Flow chart of study selection.](pone.0155273.g001){#pone.0155273.g001}
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###### Baseline characteristics of selected studies.

![](pone.0155273.t001){#pone.0155273.t001g}

  Study                                            Year   Study design    Age(PG/CG)   Sample size(PG/CG)   Stent type   Interventions           Outcomes               Follow-up                                       
  ------------------------------------------------ ------ --------------- ------------ -------------------- ------------ ----------------------- ---------------------- ----------------------------------------- ----- -----------
  Lee, H et al.\[[@pone.0155273.ref021]\]          2013   RCT             60±10/62±9   60/61                DES          pioglitazone, 15 mg/d   placebo                ISR; Late loss; Neointimal volume; MACE   TLR   12 months
  Soon Jun Hong et al.\[[@pone.0155273.ref022]\]   2011   RCT             64±7/62±8    47/47                DES          pioglitazone, 30 mg/d   placebo                ISR; Late loss; Neointimal volume; MACE   \-    8 months
  Takagi, T et al.\[[@pone.0155273.ref023]\]       2009   RCT             64±9/62±10   48/49                BES          pioglitazone, 30 mg/d   placebo                ISR; Late loss; MACE                      TLR   6 months
  Yokoyama, J et al.\[[@pone.0155273.ref024]\]     2007   Retrospective   63±10/64±9   56/37                BES          pioglitazone, 15 mg/d   without pioglitazone   ISR; Late loss                            TLR   6 months
  Nishio, K et al.\[[@pone.0155273.ref025]\]       2006   RCT             66±9/68±10   26/28                BES          pioglitazone, 30 mg/d   without pioglitazone   ISR; Late loss                            \-    6 months
  Takagi, T et al.\[[@pone.0155273.ref026]\]       2003   RCT             64±10/65±9   23/21                BES          pioglitazone, 30 mg/d   without pioglitazone   ISR; Neointimal volume                    TLR   6 months

PG = pioglitazone group; CG = control group; DES = drug-eluting stent; BES = bare-metal stent; ISR = in-stent restenosis; TLR = target lesion revascularization; MACE = major adverse cardiac events.

The quality assessment and publication bias {#sec014}
-------------------------------------------

The assessment of study quality was performed by application of Modified Jadad scale, which is composed of randomization method, double-blinding, withdrawals and dropouts and allocation concealment\[[@pone.0155273.ref027]\]. The Jadad scores of the studies are summarized in [Table 2](#pone.0155273.t002){ref-type="table"}. The publication bias was assessed by a funnel plot, which was based on the outcome of ISR ([Fig 2](#pone.0155273.g002){ref-type="fig"}), and no publication bias was found (Begg's test, P = 0.707).

![Funnel plot for the events of ISR.](pone.0155273.g002){#pone.0155273.g002}

10.1371/journal.pone.0155273.t002

###### Methodologic quality assessment of selected studies.

![](pone.0155273.t002){#pone.0155273.t002g}

  Author                                           Randomization   Randomization method   Blinding       Withdrawals/dropouts   Allocation concealment   Scores
  ------------------------------------------------ --------------- ---------------------- -------------- ---------------------- ------------------------ --------
  Lee, H et al.\[[@pone.0155273.ref021]\]          Yes             Unclear                Unclear        No                     Unclear                  3
  Soon Jun Hong et al.\[[@pone.0155273.ref022]\]   Yes             Unclear                single blind   Yes                    Unclear                  3
  Takagi, T et al.\[[@pone.0155273.ref023]\]       Yes             Unclear                open label     No                     Unclear                  2
  Yokoyama, J et al.\[[@pone.0155273.ref024]\]     No              No                     No             No                     No                       0
  Nishio, K et al.\[[@pone.0155273.ref025]\]       Yes             Unclear                Unclear        No                     Unclear                  3
  Takagi, T et al.\[[@pone.0155273.ref026]\]       Yes             Unclear                double blind   No                     Unclear                  4

Statistical Analysis Results {#sec015}
----------------------------

### In Stent Restenosis {#sec016}

There was no significant heterogeneity among the six studies\[[@pone.0155273.ref021]--[@pone.0155273.ref026]\] (I^2^ = 14.5%, P = 0.322), so the FE model was used. In the six studies, the events of ISR occurred in 41 of 249 patients (16.5%) treated with pioglitazone and in 72 of 227 patients (31.7%) without pioglitazone treatment. The use of pioglitazone was associated with a significant reduction in the events of ISR (RR 0.48, 95% CI 0.35 to 0.68, P\<0.001) ([Fig 3](#pone.0155273.g003){ref-type="fig"}).

![RR of the events of ISR.](pone.0155273.g003){#pone.0155273.g003}

### Late Loss {#sec017}

The late loss was reported after pioglitazone treatment in the diabetic patients suffered from PCI in 5 studies\[[@pone.0155273.ref021]--[@pone.0155273.ref025]\]. There was considerable heterogeneity among these studies (I^2^ = 81.9%, P\<0.001). As a result, the data about late loss in the studies were not suitable for further analysis.

### Neointimal Volume {#sec018}

The neointimal volume of the target lesion was investigated by IVUS at 1 year follow-up in 3 studies\[[@pone.0155273.ref021],[@pone.0155273.ref022],[@pone.0155273.ref026]\]. After pooling the data of the studies, we were not able to perform further analysis for the results of neointimal volume because of the considerable heterogeneity among the studies (I^2^ = 75.9%, P = 0.016).

### Target Lesion Revascularization {#sec019}

The meta-analysis was performed with FE model for there was no significant heterogeneity among the 4 studies \[[@pone.0155273.ref021],[@pone.0155273.ref023],[@pone.0155273.ref024],[@pone.0155273.ref026]\] (I^2^ = 6.0%, P = 0.363). Pioglitazone treatment was associated with a significant reduction in the events of TLR (RR 0.58, 95%CI 0.38 to 0.87, P = 0.009) ([Fig 4](#pone.0155273.g004){ref-type="fig"}).

![RR of the events of TLR.](pone.0155273.g004){#pone.0155273.g004}

### Major Adverse Cardiac Events {#sec020}

The incidence of MACE was reported in three studies\[[@pone.0155273.ref021]--[@pone.0155273.ref023]\], and there was no significant heterogeneity among them (I^2^ = 36.7%, P = 0.209). After the application of FE model for the meta-analysis, the result showed there was no association between the treatment of pioglitazone and MACE (RR 0.56, 95%CI 0.30 to 1.05, P = 0.071) ([Fig 5](#pone.0155273.g005){ref-type="fig"}).

![RR of the events of MACE.](pone.0155273.g005){#pone.0155273.g005}

Discussion {#sec021}
==========

Inflammation response evoked by stent implantation, which initiates several vascular remodeling processes including neointimal hyperplasia, is crucial contributor to the development of restenosis after PCI\[[@pone.0155273.ref028]\], especially in patients with T2DM\[[@pone.0155273.ref029]\]. As anti-diabetic agents involved in insulin sensitivity and lipid metabolism, TZDs can activate PPAR-γ, which is highly expressed in activated macrophages after PCI\[[@pone.0155273.ref030]\], to exert its anti-inflammatory and anti-proliferative effect in the process of ISR\[[@pone.0155273.ref031]--[@pone.0155273.ref034]\]. However, among the three TZDs, troglitazone is not approved due to its liver toxicity\[[@pone.0155273.ref008]\], and rosiglitazone is associated with increased risk of myocardial infarction\[[@pone.0155273.ref006]\]. So, as the only one which shows beneficial effects on cardiovascular outcomes in TZDs, pioglitazone is considered to be a more promising drug on the prevention of ISR\[[@pone.0155273.ref023],[@pone.0155273.ref035]\].

Although the incidence of ISR was markedly reduced since DES have been widely used \[[@pone.0155273.ref036],[@pone.0155273.ref037]\], a fairly high rate of ISR (10.1% to 17.6%) after DES implantation still exists in patients with T2DM\[[@pone.0155273.ref010],[@pone.0155273.ref038]\], which probably due to the amplified inflammatory response and increased neointimal hyperplasia. Therefore, diabetes is one of the most powerful clinical predictors of ISR after PCI regardless of the kind of stents used\[[@pone.0155273.ref001],[@pone.0155273.ref010],[@pone.0155273.ref011],[@pone.0155273.ref039]\]. Besides, little data is available about the dosage of pioglitazone that can appropriately prevent ISR after PCI with DES, especially in T2DM patients. Therefore, we made the meta-analysis without selection of the kind of stent and the dosage of pioglitazone, which might mainly account for the considerable heterogeneity of late loss and neointimal volume. Nevertheless, as the results have shown, no statistical heterogeneity was found among the included studies for most endpoints, indicating that the results of the study are convincing in some degree.

This study, comprising 503 T2DM patients, demonstrates that the use of pioglitazone was associated with a reduction in ISR and TLR. Although late loss and neointimal volume were not further analyzed due to the considerable heterogeneity among the studies, the beneficial effects of pioglitazone on these endpoints could not be ignored \[[@pone.0155273.ref022],[@pone.0155273.ref023],[@pone.0155273.ref025],[@pone.0155273.ref026]\]. The benefits of pioglitazone for T2DM patients could be attributed to its favorable effect on lipid profile\[[@pone.0155273.ref040]\], attenuation of atherosclerotic plaque inflammation\[[@pone.0155273.ref004]\] and efflux of cholesterol from macrophages\[[@pone.0155273.ref041]\]. In this regards, Pioglitazone could be an useful agent on the prevention of ISR \[[@pone.0155273.ref042]--[@pone.0155273.ref044]\]. However, it is worth noting that no studies, including this meta-analysis, have found that pioglitazone reduces cardiovascular events, even the best available data for pioglitazone from the PROactive trial\[[@pone.0155273.ref045]\]. For this reason, the results of the study should be interpreted with care and more high quality clinical trials are needed.

Several limitations should be considered in this study. First, for only six studies met our inclusion criteria, the publication bias of the study could not be totally excluded for the low power of funnel plot asymmetry test. Second, the considerable heterogeneity mentioned above, together with the small sample size, lower quality of the RCT trials (Modified Jadad score ranged from 0--4) and the enrollment of one retrospective study, could make the conclusion less convincing. Finally, the lack of subgroup analysis, such as condition of the patients, selection of the stents and the dosage of pioglitazone might also lead to significant bias in the study. Therefore, the results of the study should be interpreted with caution and additional clinical trials are required.

Conclusions {#sec022}
===========

The limited evidence indicates that the treatment of pioglitazone is associated with a reduction in ISR and TLR in T2DM patients suffering from PCI, except the incidence of MACE. However, due to the limitations of the present study, additional high quality RCTs are needed and the results of the study should be interpreted with care.
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